This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Noble, S. I. Articles by Finlay, I G Search for Related Content PubMed PubMed Citation Articles by Noble, S. I. Articles by Finlay, I G Social Bookmarking                         What's this?

Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study

I G Finlay

Department of Palliative Medicine, Velindre Hospital, Cardiff

Venous thromboembolism (VTE) is common in patients with terminal cancer. Current treatment practice with warfarin has a high incidence of complications, including bleeding, poor control and recurrent VTE. Long-term low-molecular-weight heparin (LMWH) therapy is safer and more efficacious in this patient group, but there are concerns that daily therapy may have a negative impact on quality of life. A qualitative study was carried out to determine whether LMWH was acceptable in palliative care patients, both in the community and in-patient units. Forty palliative care patients receiving LMWH for VTE were interviewed. Participants found LMWH to be an acceptable intervention, allowing them freedom from blood tests and optimism regarding their care. It was considered a preferable therapy to warfarin, which had a negative impact on participant's quality of life. The findings of this study support the use of LMWH, first line in the treatment of established VTE in the palliative care setting.

Key Words: acceptability • cancer • low-molecular-weight heparin • palliative care • qualitative • venous thromboembolism

Palliative Medicine, Vol. 19, No. 3, 197-201 (2005)
DOI: 10.1191/0269216305pm1008oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				B. BABU and T. L. CARMAN Cancer and clots: All cases of venous thromboembolism are not treated the same Cleveland Clinic Journal of Medicine, February 1, 2009; 76(2): 129 - 135. [Abstract] [Full Text] [PDF]

				M. Soto-Cardenas, G Pelayo-Garcia, A Rodriguez-Camacho, E Segura-Fernandez, A Mogollo-Galvan, and J. Giron-Gonzalez Venous thromboembolism in patients with advanced cancer under palliative care: additional risk factors, primary/secondary prophylaxis and complications observed under normal clinical practice Palliative Medicine, December 1, 2008; 22(8): 965 - 968. [Abstract] [PDF]

				A F. Howard Review: low-molecular-weight heparin prevented recurrent VTE more than oral anticoagulants in patients with cancer Evid. Based Nurs., October 1, 2008; 11(4): 117 - 117. [Full Text] [PDF]

				K. Flemming, J. Adamson, and K. Atkin Improving the effectiveness of interventions in palliative care: the potential role of qualitative research in enhancing evidence from randomized controlled trials Palliative Medicine, March 1, 2008; 22(2): 123 - 131. [Abstract] [PDF]

				S Noble The challenges of managing cancer related venous thromboembolism in the palliative care setting Postgrad. Med. J., November 1, 2007; 83(985): 671 - 674. [Abstract] [Full Text] [PDF]

				S.I.R. Noble, K. Hood, and I.G. Finlay The use of long-term low-molecular weight heparin for the treatment of venous thromboembolism in palliative care patients with advanced cancer: a case series of sixty two patients Palliative Medicine, September 1, 2007; 21(6): 473 - 476. [Abstract] [PDF]

				S I R Noble, A Nelson, C Turner, and I G Finlay Acceptability of low molecular weight heparin thromboprophylaxis for inpatients receiving palliative care: qualitative study BMJ, March 11, 2006; 332(7541): 577 - 580. [Abstract] [Full Text] [PDF]